GlassScriptPhysician profile
Geoffrey A Potts
NPI 1598052441
$10,517.34
in general payments reported to CMS, 2019-2025
42 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,479 · 2020: $2,164 · 2021: $929 · 2022: $1,164 · 2023: $1,496 · 2024: $1,417 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,781.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,918.16 | 2019-2025 | |
| Abbvie INC. | $2,014.01 | 2019-2025 | |
| Janssen Biotech, INC. | $1,570.33 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $588.90 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $459.23 | 2020-2025 | Dupixent, Libtayo |
| Ucb, INC. | $424.78 | 2020-2025 | Bimzelx |
| Leo Pharma INC. | $406.30 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $288.24 | 2021-2025 | |
| Lilly USA, LLC | $227.76 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $209.18 | 2021-2025 | Nemluvio, Aklief |
| Genentech USA, INC. | $181.67 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $99.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.23 | 2023-2024 | Spevigo, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $92.73 | 2023-2024 | Sotyktu |
| Amgen INC. | $83.98 | 2019-2024 | Otezla |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $79.46 | 2023-2024 | Idacio |
| Kerecis Limited | $65.88 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Merck Sharp & Dohme LLC | $62.28 | 2023-2024 | Keytruda |
| Mallinckrodt Hospital Products INC. | $52.41 | 2023-2025 | Acthar, Cellex |
| Dermira, INC. | $50.33 | 2019-2020 | |
| Kyowa Kirin, INC. | $48.89 | 2025 | |
| Mylan Institutional INC. | $47.29 | 2023 | Hulio |
| Incyte Corporation | $45.10 | 2021-2024 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $43.16 | 2019-2023 | Valchlor |
| Organogenesis INC. | $40.83 | 2023-2024 | Puraply |
| Dermavant Sciences, INC. | $37.48 | 2023-2024 | Vtama |
| Teleflex LLC | $35.09 | 2024-2025 | Urolift, Barrigel |
| Krystal Biotech INC | $28.74 | 2023 | Vyjuvek |
| Vyne Pharmaceuticals INC. | $24.40 | 2021 | |
| Celgene Corporation | $23.95 | 2019 | |
| Organon LLC | $22.73 | 2023 | Hadlima |
| 180 Medical, INC. | $21.99 | 2024 | |
| Hartmann USA, INC. | $18.50 | 2024 | Zetuvit Plus 10x10 P10 |
| Sun Pharmaceutical Industries INC. | $17.40 | 2020 | |
| Arcutis Biotherapeutics, INC. | $16.62 | 2025 | Zoryve |
| Hologic Sales and Service, LLC | $16.10 | 2025 | Thinprep 2000 Processor, Aptima |
| Chiesi USA, INC. | $15.25 | 2024 | Filsuvez |
| Acera Surgical, INC. | $15.12 | 2025 | Restrata Wound Matrix |
| Mimedx Group, INC. | $14.78 | 2024 | |
| Biofrontera INC. | $14.00 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Potts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.